Why Pacira BioSciences Stock Is Having Its Best Day Ever After $1.7 Billion Viatris Acquisition
Viatris has agreed to acquire Pacira BioXciences, acquiring its portfolio of non-opioid pain medications. Continue Reading
YENOM NOTICIAS
Qué está moviendo el mercado.
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Pacira BioSciences Stock Surges 44% on $1.7 Billion Viatris Acquisition
Viatris has agreed to acquire Pacira BioXciences, acquiring its portfolio of non-opioid pain medications. Continue Reading
Andrew Hill Investment Fund Sees More Growth Ahead for Vertex (VRTX): Here’s Why
Andrew Hill Investment Advisors recently released its third-quarter 2026 investor letter. A copy of the letter can be downloaded here. The fund navigated a mixed third-quarter investment environment in which rising oil prices, higher inter…
Vertex to Announce Third Quarter 2026 Financial Results November 2nd
BOSTON, October 07, 2026--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2026 financial results on Monday, November 2, 2026, after the financial markets close. The company will host a conf…
NVIDIA And 2 Elite Undervalued Stocks To Own
Global public debt now sits near 100% of GDP, and the IMF is signaling a return to spending cuts and tighter money. That kind of backdrop often pushes investors toward companies that generate solid cash, carry sensible debt levels, and sti…
Novavax (NVAX) Surges 20.1%: Is This an Indication of Further Gains?
Novavax NVAX shares soared 20.1% in the last trading session to close at $12.56. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 2.4% gain over the past four we…
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know
Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Shares of this…
Vortex Energy Commissions Hydrogen and Helium Study at Robinsons River Salt Project
VORTEX ENERGY CORP Desktop study will use existing geological, geophysical and well data to assess natural hydrogen and helium potential VANCOUVER, British Columbia, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: V…
2 Safe-and-Steady Stocks with Promising Prospects and 1 We Turn Down
2 Safe-and-Steady Stocks with Promising Prospects and 1 We Turn Down A stock with low volatility can be reassuring, but it doesn't always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward o…
Vertex (VRTX) or Regeneron (REGN)? Two Biotech Moats, Two Very Different Bets
Biotech companies are strange businesses to think about in terms of competitive advantages. A software company can lock customers into an ecosystem for years. A manufacturer can have a cost advantage. A biotech company, meanwhile, can spen…
Vertex Pharmaceuticals And 2 Other Top Gene Therapy Stocks
Global bond yields recently hit multidecade highs, raising borrowing costs and putting pressure on many high growth sectors. When money gets more expensive, investors often look harder at balance sheets and valuations. That is where select…
Vertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to Know
In the latest close session, Vertex Pharmaceuticals (VRTX) was down 3.07% at $506.74. The stock trailed the S&P 500, which registered a daily gain of 0.2%. Elsewhere, the Dow gained 0.04%, while the tech-heavy Nasdaq added 0.04%. Shares of…
Vortex Energy Completes Acquisition of the Meadows Project in Saskatchewan
VORTEX ENERGY CORP VANCOUVER, British Columbia, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) ("Vortex" or the "Company") is pleased to announce that, further to its news release dated September…
Could Vertex Pharmaceuticals (VRTX)’s Kidney Breakthrough Unlock a New Opportunity for Maze Therapeutics (MAZE)?
On September 22, Truist analyst Danielle Brill identified a "significant positive readthrough" for Maze Therapeutics, Inc. (NASDAQ:MAZE) following positive Phase 2 topline data from Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). The da…
2 Healthcare Stocks to Target This Week and 1 We Avoid
2 Healthcare Stocks to Target This Week and 1 We Avoid From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry have been rewarded lately…
Biogen (NASDAQ:BIIB) Q2 Earnings: Leading The Therapeutics Pack
Biogen (NASDAQ:BIIB) Q2 Earnings: Leading The Therapeutics Pack As the Q2 earnings season comes to a close, it's time to take stock of this quarter's best and worst performers in the therapeutics industry, including Biogen (NASDAQ:BIIB) an…
Maze Therapeutics (MAZE) Shares Moved, So What Is Driving Attention Now?
Fresh Coverage Puts Maze Therapeutics in Focus Maze Therapeutics (MAZE) moved higher in pre-market trading on 23 September after CIBC began covering the clinical-stage kidney and metabolic disease specialist, with the share reaction unfold…
Vertex Pharmaceuticals (VRTX) Increases Despite Market Slip: Here's What You Need to Know
Vertex Pharmaceuticals (VRTX) closed at $522.38 in the latest trading session, marking a +1.17% move from the prior day. This change outpaced the S&P 500's 0.03% loss on the day. Meanwhile, the Dow experienced a drop of 0.31%, and the tech…
Will Vertex's Kidney Disease Pipeline Be a New Growth Engine?
Vertex Pharmaceuticals Incorporated VRTX has established a dominant position in the cystic fibrosis (CF) market through its portfolio of CFTR modulators, including Trikafta/Kaftrio and the newer Alyftrek. Vertex's marketed CF therapies are…
Vertex (VRTX) Stock Could Be 24% Undervalued As Kidney Trial Progress Continues
Vertex Pharmaceuticals has ridden a powerful five year share price run while pushing deeper into kidney disease, endocrinology and pain treatments, which puts fresh attention on what investors are really paying for its cash flows today. Wi…
Vertex Posts Positive Phase II Data on Kidney Disease Drug
Vertex Pharmaceuticals VRTX announced positive data from the phase IIb AMPLIFIED study, which evaluated its investigational drug, inaxaplin, for the treatment of patients with APOL1-mediated kidney disease ("AMKD") and modest proteinuria a…
Autologous Hematopoietic Stem Cell Gene Therapy Market Global Report 2026: A $13.44 Billion Market by 2030 as Novartis, Vertex, CRISPR Therapeutics and Orchard Therapeutics Accelerate the Gene-Editing Race
Company Logo Boost ROI via rare-disease R&D, CRISPR therapies, scalable manufacturing, CDMO partnerships and regulatory incentives that accelerate approvals and commercialization. Autologous Hematopoietic Stem Cell Gene Therapy MarketAutol…
The Surprise That Sent Vertex — And Its Chief Rival — Soaring
Vertex stock popped Tuesday — while shares of rival Maze Therapeutics skyrocketed — on a surprise expansion for their kidney disease drugs. Continue Reading
Vertex’s Kidney Drug Success Sparks a 22% Surge for This Rival Biotech
Maze Therapeutics stock jumped after Vertex Pharmaceuticals reported positive results for inaxaplin, boosting confidence in a rival treatment from Maze. Continue Reading
ABCL Stock Surges 121% in 3 Months: Here's What You Need to Know
AbCellera Biologics ABCL has delivered a sharp rally over the past three months, with the stock soaring 121% compared with the industry's 6.6% growth. The move has been driven primarily by a combination of strong clinical progress for its…
Chronic Kidney Disease (CKD) Market Gains Momentum as Pipeline Innovation and Clinical Trials Reshape the Competitive Landscape in 2026
Company Logo CKD drug development is shifting toward disease-modifying and cardiorenal therapies, creating opportunities in early detection, high-risk screening, combinations and licensing Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- "Chroni…
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of this drugmaker have return…
Vertex Announces Positive Results From Phase 2b AMPLIFIED Study of Inaxaplin in Additional Populations of People With APOL1-Mediated Kidney Disease (AMKD) and Completion of Enrollment in the Phase 2/3 AMPLITUDE Trial
– In people with AMKD with modest proteinuria, treatment with inaxaplin led to a reduction in urine albumin to creatinine ratio (UACR) of -42.7% at Week 13 compared to baseline – - In people with AMKD and type 2 diabetes, treatment with in…
FDA, Duke-Margolis workshop to examine evidence standards for rare diseases
[Scientists inside a laboratory] Hinterhaus Productions The Food and Drug Administration and Duke-Margolis Institute for Health Policy will convene a public workshop this month to examine one of the most difficult questions in rare disease…
3 Reasons CRISPR Therapeutics Stock Is Still a Buy After a Rocky 2026
It's been a disappointing couple of years for shareholders of biotechnology outfit CRISPR Therapeutics (NASDAQ: CRSP). This stock's barely up since the end of 2022, lagging the broad market's gains. It's not the performance that investors…
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: Here's Why
Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $508.34, moving -1.55% from the previous trading session. The stock's performance was behind the S&P 500's daily gain of 0.17%. At the same time, the Dow lost 0.18%, and t…
2 Reasons to Like VRTX (and 1 Not So Much)
2 Reasons to Like VRTX (and 1 Not So Much) Vertex Pharmaceuticals has followed the market's trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 13.9% to $514.18 per share while the index…
Is This Biotech Stock Too Cheap to Ignore After Its Latest Pullback?
Vertex Pharmaceuticals (NASDAQ: VRTX) has performed well in 2026. Its shares are up 13% year-to-date, while the S&P 500 is up 10%. However, after reaching $560.25 per share earlier this year, the company has dropped 8% from that 52-week hi…
Vortex Energy Enters Into Asset Purchase Agreement to Acquire the Meadows Project in Saskatchewan
VORTEX ENERGY CORP VANCOUVER, British Columbia, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) ("Vortex" or the "Company") is pleased to announce that it has entered into an asset purchase agreem…
Gene-Editing Powerhouse And Its Rivals Surge Toward A Breakout
Crispr stock, alongside other gene-editing equities, pulled a bullish move Thursday — bounding for a breakout from a cup-with-handle base. Continue Reading
SION to Cut Workforce by Nearly Half After CF Study Failure, Stock Down
Shares of Sionna Therapeutics SION declined nearly 17% yesterday after the company announced a major organizational restructuring. As part of the restructuring, Sionna intends to reduce its workforce by about 46% to lower operating expense…